Advanced Proteome Therapeutics (TSXV:APC.H) Market Cap: C$0.21 Mil (As of Jun. 25, 2026)


What is Advanced Proteome Therapeutics Market Cap?

Advanced Proteome Therapeutics TSXV:APC.H Market Cap is C$0.21 Mil as of Jun. 25, 2026.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Advanced Proteome Therapeutics's share price for the quarter that ended in Apr. 2023 was C$0.015. Advanced Proteome Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Apr. 2023 was 41.13 Mil. Therefore, Advanced Proteome Therapeutics's market cap for the quarter that ended in Apr. 2023 was C$0.62 Mil.

Advanced Proteome Therapeutics's quarterly market cap declined from Oct. 2022 (C$1.98 Mil) to Jan. 2023 (C$1.65 Mil) and declined from Jan. 2023 (C$1.65 Mil) to Apr. 2023 (C$0.62 Mil).

Advanced Proteome Therapeutics's annual market cap increased from Jul. 2020 (C$2.57 Mil) to Jul. 2021 (C$13.21 Mil) but then declined from Jul. 2021 (C$13.21 Mil) to Jul. 2022 (C$5.95 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Advanced Proteome Therapeutics's Enterprise Value for Today is C$0.20 Mil.

Advanced Proteome Therapeutics  (TSXV:APC.H) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Advanced Proteome Therapeutics Market Cap Related Terms

Advanced Proteome Therapeutics Market Cap Historical Data

* Premium members only.

The historical data trend for Advanced Proteome Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics Market Cap Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.83 3.04 2.57 13.21 5.95

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.94 5.95 1.98 1.65 0.62

TSXV:APC.H vs VRTX, REGN, SGEN: Market Cap Comparison

For the Biotechnology subindustry, Advanced Proteome Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Proteome Therapeutics Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's Market Cap falls into.


Advanced Proteome Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Advanced Proteome Therapeutics's Market Cap for the fiscal year that ended in Jul. 2022 is calculated as

Market Cap (A: Jul. 2022 )=Share Price (A: Jul. 2022 )*Shares Outstanding (EOP) (A: Jul. 2022 )
=C$0.15*39.677
=C$5.95

Advanced Proteome Therapeutics's Market Cap for the quarter that ended in Apr. 2023 is calculated as

Market Cap (Q: Apr. 2023 )=Share Price (Q: Apr. 2023 )*Shares Outstanding (EOP) (Q: Apr. 2023 )
=C$0.015*41.127
=C$0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of C$0.21 Mil mean?
Advanced Proteome Therapeutics (TSXV:APC.H) has a Market Cap of C$0.21 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Advanced Proteome Therapeutics and its competitors.
Is Advanced Proteome Therapeutics' Market Cap too high?
Advanced Proteome Therapeutics' current Market Cap is C$0.21 Mil.
How does Advanced Proteome Therapeutics' Market Cap compare to VRTX and REGN?
Advanced Proteome Therapeutics' Market Cap of C$0.21 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 117.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.26, based on 1,430 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Advanced Proteome Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 117.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Proteome Therapeutics's current Market Cap is C$0.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Proteome Therapeutics stock overvalued right now?
Advanced Proteome Therapeutics (TSXV:APC.H) has a current Market Cap of C$0.21 Mil. The current Market Cap is C$0.21 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Advanced Proteome Therapeutics (TSXV:APC.H), the current Market Cap is C$0.21 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Proteome Therapeutics Business Description

Address 104 8337 Eastlake Drive, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.